VECT VectivBio Holding AG

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD) for $17.00 per share in cash. The firm is examining whether this consideration and the sale process adequately value VectivBio, suggesting the company might be undervalued. Shareholders are encouraged to contact KSF if they believe the transaction undervalues the company or wish to discuss their legal rights, noting the time-sensitive nature of the tender offer.

Ironwood Pharmaceuticals, Inc. successfully completed its tender offer to acquire VectivBio Holding AG shares for $17.00 per share, with approximately 97.60% of outstanding shares tendered. Following the acquisition, VectivBio's directors have been replaced by Ironwood-appointed directors. Ironwood plans to delist VectivBio shares from Nasdaq and conduct a squeeze-out merger under Swiss law for the remaining shares.

Ironwood Pharmaceuticals Inc. announced its acquisition of VectivBio Holding AG for $1 billion, integrating GLP2 analog apraglutide into its gastrointestinal portfolio. VectivBio, a 2019 spinout, had advanced apraglutide into Phase III testing for short bowel syndrome. Additionally, Krystal Biotech Inc. raised $160 million in a PIPE transaction following FDA approval of Vyjuvek for dystrophic epidermolysis bullosa, with a Q3 2023 launch anticipated.

Ironwood Pharmaceuticals, Inc. announced its definitive agreement to acquire VectivBio Holding AG for approximately $1 billion in an all-cash transaction. The acquisition price of $17.00 per share represents an 80% premium over VectivBio's volume-weighted average share price. This strategic move aims to strengthen Ironwood's GI portfolio with VectivBio's lead investigational asset, apraglutide, a GLP-2 analog for Short Bowel Syndrome with Intestinal Failure (SBS-IF), which has potential peak net sales of $1 billion.

Ironwood Pharmaceuticals announced its plan to acquire Swiss biotech firm VectivBio Holding AG for $1 billion. This all-cash offer strengthens Ironwood's focus on gastrointestinal treatments and will add apraglutide, an experimental drug for short bowel syndrome, to its pipeline. The deal, representing an 80 percent premium on VectivBio’s average share price, is expected to close in the second half of the year.

Ironwood Pharmaceuticals Inc is set to acquire VectivBio Holding AG for $1.15 billion, paying $17 per share. This strategic move aims to enhance Ironwood's portfolio of experimental digestive disorder drugs, particularly with VectivBio's apraglutide, which is projected to achieve $1 billion in peak net sales. The acquisition seeks to diversify Ironwood's revenue stream beyond its current reliance on the bowel disease drug Linzess.